Podhorna, J., Hake, S., Zhao, Y., Groeschl, M., Pollentier, S., Atkins, A., & Keefe, R. (2019). P.244 Novel endpoints of motivation and reinforcement learning in a large interventional clinical trial of BI 425809 in patients with schizophrenia. In European Neuropsychopharmacology (Vol. 29, pp. S187–S188). Elsevier BV. https://doi.org/10.1016/j.euroneuro.2019.09.286

Podhorna, J., S. Hake, Y. Zhao, M. Groeschl, S. Pollentier, A. Atkins, and R. Keefe. “P.244 Novel endpoints of motivation and reinforcement learning in a large interventional clinical trial of BI 425809 in patients with schizophrenia.” In European Neuropsychopharmacology, 29:S187–88. Elsevier BV, 2019. https://doi.org/10.1016/j.euroneuro.2019.09.286.

Podhorna J, Hake S, Zhao Y, Groeschl M, Pollentier S, Atkins A, et al. P.244 Novel endpoints of motivation and reinforcement learning in a large interventional clinical trial of BI 425809 in patients with schizophrenia. In: European Neuropsychopharmacology. Elsevier BV; 2019. p. S187–8.

Podhorna, J., et al. “P.244 Novel endpoints of motivation and reinforcement learning in a large interventional clinical trial of BI 425809 in patients with schizophrenia.” European Neuropsychopharmacology, vol. 29, Elsevier BV, 2019, pp. S187–88. Crossref, doi:10.1016/j.euroneuro.2019.09.286.

Podhorna J, Hake S, Zhao Y, Groeschl M, Pollentier S, Atkins A, Keefe R. P.244 Novel endpoints of motivation and reinforcement learning in a large interventional clinical trial of BI 425809 in patients with schizophrenia. European Neuropsychopharmacology. Elsevier BV; 2019. p. S187–S188.